dc.creator | Shah, Kiran | |
dc.creator | Tiwaskar, Mangesh | |
dc.creator | Chawla, Purvi | |
dc.creator | Kale, Mayura | |
dc.creator | Deshmane, Rajesh | |
dc.creator | Sowani, Alpana | |
dc.date.accessioned | 2020-08-21T16:03:24Z | |
dc.date.accessioned | 2022-09-23T18:56:41Z | |
dc.date.available | 2020-08-21T16:03:24Z | |
dc.date.available | 2022-09-23T18:56:41Z | |
dc.date.created | 2020-08-21T16:03:24Z | |
dc.identifier | https://doi.org/10.1016/j.dsx.2020.07.003 | |
dc.identifier | http://hdl.handle.net/20.500.12010/12087 | |
dc.identifier | https://doi.org/10.1016/j.dsx.2020.07.003 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3510116 | |
dc.description.abstract | Background: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to
be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19)
pandemic has further complicated the issue of hypoglycemia due to limitations in access to food,
outpatient clinics, pathological services and medicines.
Aim: To assess the factors associated with the risk of hypoglycemia during AprileMay 2020 lockdown in
people with type 2 diabetes mellitus.
Methodology: We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM)
reporting to the emergency department (ED) during lockdown period with symptoms suggestive of
hypoglycemia.
Results: The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean
random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin
and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed
by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value
(50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU
(60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ)
400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment
reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and
coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%,
and 32.88%) respectively.
Conclusion: The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with
T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities.
Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia | |
dc.language | eng | |
dc.publisher | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | |
dc.rights | info:eu-repo/semantics/embargoedAccess | |
dc.rights | Acceso restringido | |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | |
dc.subject | Hypoglycemia | |
dc.subject | Anti-diabetic agents | |
dc.subject | COVID-19 | |
dc.subject | Comorbidities | |
dc.title | Hypoglycemia at the time of Covid-19 pandemic | |